Skip to main content
. 2023 Aug 30;17(17):16432–16447. doi: 10.1021/acsnano.2c12857

Figure 4.

Figure 4

Development and characterization of EVs encapsulating Cas9 protein and sgRNA. (A) Ang and TAT peptide are modified to EVs membrane surface to obtain engineered EVs with glioma targeting and tumor-penetrating functions. (B) Biomarkers of EVs detected by Immunoblot. (C–D) DLS and TEM the image of purified EVs. (E) Loading capabilities of various exogenous approaches. (F) Immunoblot analysis to determine the loading efficiency of Cas9 protein in EVs. (G) Frequency of GSS indel mutation detected by T7EI assay. (H) DNA sequencing results of GSS gene editing in LN229 cells treated with Ang/TAT-sgGSS-EVs.